BTK and diffuse large B-cell lymphoma: BTK inhibitors have been attributed to activity in R/R DLBCL [11,12]. Additionally, BTK inhibitors have also been theorized to have a beneficial effect on CAR-T cell function by enhancing expansion, viability, and engraftment, and improving activation and effector function [13-15].